Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 311 publications.

Raza S, Heyes A, Leonard C, D'Souza V, Carney R, Mackie D, Gelinas D, Swijsen A. Analysis of the burden of illness, treatment, and health disparities in amyotrophic lateral sclerosis. Poster to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Rao S, McQuay LJ, Forns J, MacKay R, Danysh HE, Doshi D, Abler V, Anthony MS, Layton JB. Evaluation of mortality in users of pimavanserin compared with other atypical antipsychotics in patients with Parkinson's disease psychosis: an update. Drug Saf. 2025 Apr 9. doi: 10.1007/s40264-025-01543-8

Layton JB, Forns J, McQuay LJ, Danysh HE, Dempsey C, Anthony MS, Turner ME. Plain language summary of mortality rates of patients with Parkinson's disease psychosis who were treated either with pimavanserin or with different second-generation (atypical) antipsychotics. Futur Neurol. 2025 Feb 28;20(1). doi: 10.1080/14796708.2025.2463315

Hellwig K, Magyari M, MacDonald TM, Cesta CE, Wergeland S, Leinonen MK, Ornoy A, Vukusic S, Lauer A, Zhou X, Kawai A, Weinrib R, Arana A, Boumenna T. A multi-country cohort database study to assess pregnancy and infant outcomes after potential maternal or paternal exposure to cladribine tablets in the treatment of multiple sclerosis: the CLEAR study methods and status update1. Ther Adv Neurol Disord. 2025 Jan 27;18:175628642. doi: 10.1177/17562864241310996

Romano (DeMuro) C, Bratlee-Whhitaker E, Hartry A, Mearns E, Taylor J, Taylor G, Callahan L, Monks D, Kremer I, Lappin D, Frangiosa T, Sangodkar S, Herring WL, Gnanasakthy K, Goss D, McLeod L, Edwards T, Poulos C, DiBenedetti D, Paulsen R. Measuring what matters most to people living with Alzheimer's disease and care partners: What Matters Most quantitative research development. Poster presented at the Alzheimer's Association International Conference (AAIC) 2024; July 31, 2024. Philadelphia, PA. [abstract] Alzheimers Dement. 2025 Jan 9; 20(S4):E085103. doi: 10.1002/alz.085103

Benitez A, Andrews JS, Shah D, Mansfield C, Ross E, Rao S, Bussberg C, Galinksy J, Konermann-Bernhardt C, Lu M, Vass C. Caregiver preferences for dravet syndrome and lennox-gastaut syndrome treatments across the USA, UK, and Germany. Poster presented at the 2024 American Epilepsy Society (AES) Annual Meeting; December 7, 2024. Los Angeles, CA.

Rao S, McQuay L, Forns J, MacKay R, Aquilina T, Doshi D, Abler V, Anthony MS, Layton B. Mortality in patients with Parkinson's disease psychosis using pimavanserin versus other antipsychotics. Poster presented at the 2024 Parkinson Study Group (PSG) 33rd Annual Meeting; December 5, 2024. Nashville, TN. Previously presented at the Neuroscience Education Institute (NEI) Congress 2024.

Rao S, Forns J, Danysh HE, Calingaert B, Dempsey C, Aquilina T, Pathak S, Anthony MS, Layton JB. Natural history and clinical outcomes in patients with Alzheimer's disease-related psychosis by antipsychotic treatment status in the United States. J Alzheimers Dis. 2024 Dec;102(4):1260-70. doi: 10.1177/13872877241297361

Dave RH, Crayton H, Miravalle A, Tai MH, Wyse K, Houghton K, Hitchens A, Berkovich R. COVID-19 vaccination response in patients with multiple sclerosis treated with ofatumumab in the United States: a medical record review. Neurol Ther. 2024 Dec;13(6):1737-45. doi: 10.1007/s40120-024-00671-0

Brubaker M, Bratlee-Whitaker E, Brown TM, Partida A, Bucior I, Patel M, Clevenger C. Linguistic validation of the agitation in Alzheimer's screener for caregivers (AASC™), a novel tool based on the IPA definition of agitation in cognitive disorders. Poster presented at the 2024 International Psychogeriatric Association (IPA) Conference; September 25, 2024. Greenville, SC. [abstract] Int Psychogeriatr. 2024 Nov 27; 36(S1):79. doi: 10.1017/S1041610224001832

Rao S, McQuay L, Forns J, MacKay R, Aquilina T, Doshi D, Abler V, Anthony MS, Layton B. Mortality in patients with Parkinson's disease psychosis using pimavanserin versus other antipsychotics. Poster presented at the Neuroscience Education Institute (NEI) Congress 2024; November 8, 2024. Colorado Springs, CO.

Halsby K, Gildea L, Madhava H, Angulo FJ, Pilz A, Erber W, Moisi J, Schley K, Colosia A, Sellner J. Clinical manifestations and outcomes of tick-borne encephalitis: a systematic literature review. Ticks Tick Borne Dis. 2024 Nov 4;15(6):102407. doi: 10.1016/j.ttbdis.2024.102407

Bagnato F, Mordin M, Greene N, Mahida S, Higuchi K, van Wingerden J. Evaluating association of chronic active lesions with disability in multiple sclerosis: a systematic literature review. Poster presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2024; October 14, 2024. Las Vegas, NV. [abstract] J Manag Care Spec Pharm. 2024 Oct; 30(10-c):S155. Previously presented at the 10th Congress of the European Academy of Neurology.

Bhushan NL, DeMuro Romano C, Gras-Najjar J, Reno J, Rockwood N, Quattrone W, Adams ET, Kelly B, McLeod L, Bhavnani SP, Bocell FD, Campbell M, Kontson K, Reasner D, Zhang C, Retzky S. Remote-use applications of the amyotrophic lateral sclerosis functional rating scale-revised clinical outcome assessment tool: a scoping review. Value Health. 2024 Oct;27(10):1454-65. doi: 10.1016/j.jval.2024.05.005

Clevenger C, Brubaker M, Jackson WC, Stroud J, Peschin S, Fehnel S, Brown TM, Bratlee-Whitaker E, Bucior I, Patel M, Grossberg G. Study protocol: quantitative evaluation of the Agitation in Alzheimer's screener for caregivers (AASC™), a novel tool for improving recognition of agitation in Alzheimer's dementia. Poster presented at the Alzheimer's Association International Conference (AAIC) 2024; July 28, 2024. Philadelphia, PA.

Perreault S, Hukin J, Erker C, Silayuv EB, Hamilton MA, Kim Y, Jimenez MI, Candrilli SD. Treatment patterns and healthcare resource utilization of pediatric patients with neurofibromatosis type 1 and unresectable plexiform neurofibroma in Canada. Poster presented at the 2024 Global NF Conference; June 20, 2024. Brussels, Belgium.

Bagnato F, Mordin M, Greene N, Mahida S, Higuchi K, Wingerden J. Evaluating association of chronic active lesions with disability in multiple sclerosis: a systematic literature review. Poster presented at the 10th Congress of the European Academy of Neurology; June 29, 2024. Helenski, Finland. [abstract] Eur J Neurol. 2024 Jun; 31(Suppl 1).

Sawant R, Paret K, Petrillo J, Koenig A, Wolowacz S, Ronquest N, Rickards H. Health state utility estimates for value assessments of novel treatments in Huntington's disease: a systematic literature review. Health Qual Life Outcomes. 2024 Apr 16;22(1):33. doi: 10.1186/s12955-024-02242-1

Mansfield C, Ho KA, Pierce A, Vass C, Liu X, Boroojerdi B, Kiri S. Patient preferences for myasthenia gravis treatments: a discrete-choice experiment. Poster presented at the American Academy of Neurology (AAN) Annual Meeting 2024; April 2024. Denver, CO. [abstract] Neurology. 2024 Apr 9; 102(17 Supplement 1). doi: 10.1212/WNL.0000000000206306

Rao S, Forns J, Danysh HE, Calingaert B, Dempsey C, Aquilina T, Pathak S, Anthony MS, Layton JB. Natural history and clinical outcomes in patients with Alzheimer's disease-related psychosis in the United States. Presented at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) 2024; March 5, 2024. Lisbon, Portugal.

Callahan LF, Samsell B, DiBenedetti D, Frangiosa T, Slota C, Biggar V, Paulsen R, Lappin D, Herring WL, Romano (DeMuro) C. Evaluating elements of the care partner experience in individuals who care for people with Alzheimer's disease across the severity spectrum. Neurol Ther. 2024 Feb;13(1):53-67. doi: 10.1007/s40120-023-00558-6

Hong LS, Garcia-Albeniz X, Friesen D, Foskett N, Beau-Lejdstrom R. Use of clinical classifications software to address ICD coding transition in large healthcare databases analyzed via high-dimensional propensity scores. Pharmacoepidemiol Drug Saf. 2024 Jan 24;33(1):e5702. doi: 10.1002/pds.5702

Blumenfeld A, Mordin M, Kosa K, Castro C, Stokes J, Shah D, Buse DC. Exploring the experience of neck pain in individuals with episodic migraine. Poster presented at the International Neurotoxin Association 7th International Conference (TOXINS 2024); January 17, 2024. Barcelona, Spain. Previously presented at the American Academy of Neurology (AAN) 2023 Annual Meeting.

Spelman T, Herring WL, Acosta C, Hyde R, Jokubaitis VG, Pucci E, Lugaresi A, Laureys G, Havrdova EK, Horakova D, Eichau S, Ozakbas S, Alroughani R, Kalincik T, Duquette P, Girard M, Petersen T, Patti F, Csepany T, Granella F, Grand'Maison F, Ferraro D, Karabudak R, Jose Sa M, Trojano M, Van Pesch V, Van Mijmeersch B, Cartechini E, McCombe P, Gerlach O, Spitaleri D, Rozsa C, Hodgkinson S, Bergamaschi R, Gouider R, Soysal A, Castillo-Trivino T, Prevost J, Garber J, de Gans K, Ampapa R, Simo M, Sanchez-Menoyo JL, Iuliano G, Sas A, van der Walt A, John N, Gray O, Hughes S, De Luca G, Izquierdo G, Onofrj M, Buzzard K, Skibina O, Terzi M, Slee M, Solaro C, Oreja-Guevara C, Ramo-Tello C, Fragoso Y, Shaygannejad V, Moore F, Rajda C, Aguera Morales E, Butzkueven H. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom. J Med Econ. 2023 Dec;27(1):109-25. doi: 10.1080/13696998.2023.2293379

Clevenger C, Brubaker M, Patel M, Cummings J, Jackson WC, Stroud C, Pechin S, Bratlee-Whitaker E, Brown TM, Fehnel S, Grossberg G. One minute to recognition: the agitation in Alzheimer's screener for caregivers (AASC). Poster presented at the Gerontological Society of America's 2023 Annual Scientific Meeting; November 10, 2023. Tampa, FL.

Halsby K, Gildea L, Colosia A, Madhava H, Erber W, Angulo F, Pilz A, Schley K, Moisi J, Sellner J. The clinical spectrum of TBE infections in adult and paediatric populations in Europe: a systematic review. Poster presented at the International Symposium on Tick-Borne Pathogens and Disease (ITPD) 2023; October 24, 2023. Vienna, Austria.

Romano (DeMuro) C, Bratlee-Whitaker E, Herring WL, Callahan L, Raimundo K, Taylor J, Taylor G, Kremer I, Lappin D, Frangiosa T, Gnanasakthy K, Goss D, Paulsen R, Hartry A, DiBenedetti D. Measuring what matters most to people living with Alzheimer's disease and care partners: what matters most qualitative research. Poster presented at the 16th Clinical Trials on Alzheimer's Disease (CTAD); October 24, 2023. Boston, MA.

Fehlmann B, Thomann A, Davies E, Twiss J, Romano C, Whalley D, Mayorga M, Levy C, Lipsmeier F, Popp W, Kustermann T, Svoboda H, Nikolcheva T, Trundell D, Lindemann M, Taylor K. Patient perspectives on symptoms and functional impacts to inform a digital assessment of Parkinson's disease. Poster presented at the 2023 International Congress of Parkingson's Disease and Movement Disorders; August 27, 2023. Copenhagen, Denmark.

Tahami Monfared AA, Phan NTN, Pearson I, Mauskopf J, Cho M, Zhang Q, Hampel H. A systematic review of clinical practice guidelines for Alzheimer's disease and strategies for future advancements. Neurol Ther. 2023 Aug;12(4):1257-84. doi: 10.1007/s40120-023-00504-6

Romano CD, Slota C, Bratlee-Whitaker E, Edwards T, Herring WL, McLeod L, Callahan L, Bullok K, Raimundo K, Taylor J, Taylor G, Kremer I, Monks D, Lappin D, Frangiosa T, Gnanasakthy K, Goss D, Comer M, Paulsen R, Hartry A, DiBenedetti D. Measuring "What Matters Most™" to individuals living with Alzheimer's disease and care partners: a conceptual model of Alzheimer's disease. Poster presented at the AAIC 2023 Conference; July 16, 2023. Amsterdam, Netherlands.

Razavi M, Herring WL, Maserejian N, Pemberton-Ross P, Nejati M. Economic burden of transitions to later stages of Alzheimer's disease in Europe: elevating the sense of urgency to treat. Poster presented at the AAIC 2023 Conference; July 16, 2023. Amsterdam, Netherlands.

Shapouri S, Candrilli S, Miles L, Simpson A, Guittari CJ. Real-world treatment with risdiplam in adults with SMA: a multicenter study. Poster presented at the 2023 Annual SMA Research & Clinical Care Meeting; June 28, 2023. Orlando, FL.

Frederiksen KS, Crawford R, Hahn-Pedersen JH, Morrison R, Jeppesen R, Doward L, Weidner W. Insights from social media posts on the lived experience of alzheimer's disease. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S352. doi: 10.1016/j.jval.2023.03.2395

Clinch S, Whalley D, Ahlers S, Klupp S, Chague J, Holt T, Asadska G, Nelson L, Levy C, Staunton H. Cross-sectional and longitudinal psychometric evaluation of the pediatric quality of life inventory generic core module in autism. Poster presented at the International Society for Autism Research (INSAR) 2023; May 5, 2023. Stockholm, Sweden.

Blumenfeld AM, Mordin M, Kosa KM, Castro CV, Stokes J, Shah D, Buse DC. Exploring the experience of neck pain in individuals with episodic migraine. Poster presented at the American Academy of Neurology (AAN) 2023 Annual Meeting; April 23, 2023. Boston, MA.

Hauber B, Paulsen R, Krasa HB, Vradenburg G, Comer M, Callahan LF, Winfield J, Potashman M, Hartry A, Lee D, Wilson H, Hoffman DL, Weiberg D, Kremer IN, Taylor GA, Taylor JM, Lappin D, Martin AD, Frangiosa T, Biggar V, Slota C, Romano (DeMuro) C, DiBenedetti D. Assessing what matters to people affected by Alzheimer's disease: a quantitative analysis. Neurol Ther. 2023 Apr;12(2):505-27. doi: 10.1007/s40120-023-00445-0

DiBenedetti D, Menne H, Paulsen R, Krasa HB, Vradenburg G, Comer M, Callahan LF, Winfield J, Potashman M, Heithoff K, Hartry A, Oberdhan D, Wilson H, Hoffman DL, Weinberg D, Kremer IN, Taylor GA, Taylor JM, Lappin D, Martin AD, Hauber B, Romano (DeMuro) C. Technical review of clinical outcomes assessments across the continuum of Alzheimer's disease. Neurol Ther. 2023 Apr;12(2):571-95. doi: 10.1007/s40120-023-00443-2

Layton JB, Forns Guzman J, McQuay LJ, Danysh HE, Dempsey C, Anthony MS, Turner ME. Mortality in patients with Parkinson's disease-related psychosis treated with pimavanserin compared with other atypical antipsychotics: a cohort study. Drug Saf. 2023 Feb 1;46(2):195-208. doi: 10.1007/s40264-022-01260-6

Lansdall CJ, McDougall F, Butler LM, Delmar P, Pross N, Qin S, McLeod L, Zhou X, Kerchner GA, Doody RS. Establishing clinically meaningful change on outcome assessments frequently used in trials of mild cognitive impairment due to Alzheimer's disease. J Prev Alzheimers Dis. 2023;10(1):9-18. doi: 10.14283/jpad.2022.102

Gerbasi ME, Goss D, Petrillo J, Nejati M, Lewis S. Patient experiences in essential tremor: mapping functional impacts to existing measures using qualitative research. Poster presented at the 2023 International Congress of Parkinson's Disease and Movement Disorders; August 27, 2023. Copenhagen, Denmark. [abstract] Mov Disord. 2023; 38(Suppl 1).

Razavi M, Herring W, Gillis C, Maserejian N, Pemberton-Ross P, Nejati M. Economic burden of daily transitions to later stages of AD dementia in the US. Poster presented at the 15th Clinical Trials on Alzheimer's Disease (CTAD); December 2, 2022. San Francisco, CA.

Copley-Merriman C, D'Souza V, Arvin-Berod C, Phillips G, Verheesen P, Heyerick A, Stoykov I. Evidence gap analysis of the burden of illness and treatment of pemphigus vulgaris and foliaceus. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S41. doi: 10.1016/j.jval.2022.09.198

Fernandez M, Copley-Merriman C, Arvin-Berod C, Phillips G, Gelinas D, Weiss R, Hofman E, Tse A. Evidence gap analysis of the burden of illness and treatment of chronic inflammatory demyelinating polyneuropathy. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S34. doi: 10.1016/j.jval.2022.09.164

Yang J, Masaquel C, Arvin-Berod C, Phillips G, Godar M, Desai M, Ayguasanosa J. Evidence gap analysis of the burden of illness and treatment of primary immune thrombocytopenia. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S19. doi: 10.1016/j.jval.2022.09.094

Forns J, Danysh HE, McQuay LJ, Turner ME, Dempsey C, Anthony MS, Demos G, Layton JB. Clinical outcomes and treatment patterns of older adults with dementia‑related psychosis by dementia type in the United States. BMC geriatr. 2022 Oct 6;22(1):784. doi: 10.1186/s12877-022-03489-3.

Ainsworth C, Higuchi K, Simou E, Guyot P, Araujo L, Greene N. Relative differences in brain volume loss with teriflunomide vs other disease-modifying therapies in relapsing multiple sclerosis: a systematic review and network meta-analysis. Poster presented at the AMCP Nexus 2022; October 11, 2022. National Harbor, MD. [abstract] J Manag Care Spec Pharm. 2022 Oct; 28(10-a):S73-4. Previously presented at the ACTRIMS Forum 2022.

Mansfield C, Bullok K, Fuhs JV, Tockhorn-Heidenreich A, Andrews JS, DiBenedetti D, Matthews BR, Darling JC, Sutphin J, Hauber B. The patient voice: exploring treatment preferences in participants with mild cognitive concerns to inform regulatory decision making. Patient. 2022 Sep;15(5):551-64. doi: 10.1007/s40271-022-00576-w

Bradley Layton J, McQuay L, Forns J, Danysh H, Dempsey C, Anthony MS, Turner ME. Risk of mortality associated with pimavanserin compared with atypical antipsychotics in patients with Parkinson's disease–related psychosis. Presented at the 2022 ICPE Conference; August 27, 2022. Copenhagen, Denmark. Previously presented at the 2022 American Society of Clinical Psychopharmacology (ASCP).

Beau-Lejdstrom R, Hong LS, Garcia de Albeniz X, Floricel F, Lorenzen J, Bonfitto F, Kalilani L, Loesch C, Luscombe G, Perez-Gutthann S, Mottet I, Foskett N. Incidence of acute renal failure in patients using Levetiracetam versus other antiseizure medications: a voluntary post-authorization safety study. Drug Saf. 2022 Jul;45(7):781-90. doi: 10.1007/s40264-022-01193-0

Tahami Monfared AA, Houghton K, Zhang Q, Mauskopf J, Alzheimer’s Disease Neuroimaging Initiative. Published Erratum - Correction to: Staging disease severity using the Alzheimer's Disease Composite Score (ADCOMS): a retrospective data analysis. Neurol Ther. 2022 Jun;11(2):915-27. doi: 10.1007/s40120-022-00340-0